LXG.V - LexaGene Holdings Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.8800
+0.0400 (+4.76%)
At close: 3:44PM EST
Stock chart is not supported by your current browser
Previous Close0.8400
Open0.8700
Bid0.8600 x 0
Ask0.8800 x 0
Day's Range0.8300 - 0.9100
52 Week Range0.4500 - 0.9300
Volume286,652
Avg. Volume151,858
Market Cap75.406M
Beta (5Y Monthly)0.84
PE Ratio (TTM)N/A
EPS (TTM)-0.1140
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    LexaGene Discusses The Company's 2020 Commercialization Strategy with The Stock Day Podcast

    Phoenix, Arizona--(Newsfile Corp. - January 28, 2020) - The Stock Day Podcast welcomed LexaGene Holdings Inc. (OTCQB: LXXGF) ("the Company"), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. CEO and Founder of the Company, Dr. Jack Regan, joined Stock Day host Everett Jolly. Dr. ...

  • GlobeNewswire

    LexaGene’s Analyzer is Designed to Detect Pathogens such as the Novel Coronavirus to Help Avert a Pandemic

    BEVERLY, Mass., Jan. 27, 2020 -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a biotechnology company that develops genetic analyzers for.

  • GlobeNewswire

    Newly-developed Tests Achieve 100% Concordance on Superbug Strains from the CDC

    LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today it has expanded its number of validated tests for antibiotic resistance and has completed testing different superbug isolates provided by the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) Antibiotic Resistance (AR) Isolate Bank.

  • LexaGene Holdings (CVE:LXG) Shares Have Generated A Total Return Of 126% In The Last Three Years
    Simply Wall St.

    LexaGene Holdings (CVE:LXG) Shares Have Generated A Total Return Of 126% In The Last Three Years

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • GlobeNewswire

    LexaGene Provides Corporate Update

    LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, provides a corporate update. Dr. Jack Regan, LexaGene’s CEO and Founder states, “This financing puts the Company in a very strong position to advance our commercial development goals. Management is using these funds to expand the development team in the areas of mechanical, electrical, and software engineering to speed the Company’s ability to evaluate and finalize different components for the commercial design of the LX2™ Genetic Analyzer.

  • GlobeNewswire

    LexaGene Announces Closing of CAD$6.64 Million Financing

    LexaGene Holdings Inc. (TSX VENTURE: LXG) (OTCQB: LXXGF) ("LexaGene" or the "Company") is pleased to announce that it has closed its previously announced offering of units (the “Units”) for aggregate gross proceeds of CAD$6.64 million (the “Offering”). The Company issued 12,769,626 Units at a price of CAD$0.52 per Unit, each Unit consisting of one common share of the Company (a “Share”) and one common share purchase warrant, with each warrant entitling the holder to purchase one Share at the price of CAD$0.75 per Share until October 29, 2022. The Offering was conducted by Industrial Alliance Securities Inc. (the “Agent”).

  • CNW Group

    LexaGene Holdings Announces Filing of Final Prospectus

    BEVERLY, MA, Oct. 22, 2019 /CNW/ - LexaGene Holdings Inc. (TSX VENTURE: LXG) (OTCQB: LXXGF) ("LexaGene" or the "Company") is pleased to announce that it has filed and received a receipt for a final short form prospectus (the "Prospectus") dated October 21, 2019 with the securities regulatory authorities in each of the provinces of Canada, except the Province of Quebec, in connection with the previously announced marketed offering of units (the "Units") of a minimum amount of C$3,500,000 and a maximum of C$10,000,000 at the price of C$0.52 per Unit (the "Offering"). The Offering is being conducted on a "best efforts" agency basis by Industrial Alliance Securities Inc., the Company's agent for the Offering in Canada (the "Agent"). The Units may also be offered for sale in the United States on a private placement basis pursuant to an exemption from the registration requirements of the United States Securities Act of 1933, as amended (the "U.S. Securities Act") and applicable state laws and in such other jurisdictions outside of Canada and the United States as agreed between the Company and the Agent.

  • GlobeNewswire

    LexaGene Holdings Announces Pricing of Prospectus Offering

    LexaGene Holdings Inc. (TSX VENTURE: LXG) (OTCQB: LXXGF) ("LexaGene" or the "Company") is pleased to announce today the pricing of its marketed public offering, which was previously announced in a press release dated September 24, 2019 (the “Offering”). The Company will offer a minimum of 6,730,770 units of the Company (each a “Unit”) and a maximum of 19,230,769 Units at the price of $0.52 per Unit for minimum gross proceeds of approximately $3,500,000 and maximum gross proceeds of approximately $10,000,000. Each Unit is comprised of one common share in the capital of the Company (a “Unit Share”) and one common share purchase warrant (a “Warrant”).

  • How Much Of LexaGene Holdings Inc. (CVE:LXG) Do Insiders Own?
    Simply Wall St.

    How Much Of LexaGene Holdings Inc. (CVE:LXG) Do Insiders Own?

    Every investor in LexaGene Holdings Inc. (CVE:LXG) should be aware of the most powerful shareholder groups. Insiders...

  • GlobeNewswire

    LexaGene Holdings Announces Proposed Offering of Units and Filing of Preliminary Prospectus

    LexaGene Holdings Inc. (TSX VENTURE: LXG) (OTCQB: LXXGF) ("LexaGene" or the "Company") is pleased to announce that it has filed a preliminary short form prospectus (the “Prospectus”) with the securities regulatory authorities in each of the provinces of Canada, except the Province of Quebec, in connection with a proposed marketed offering of units (the “Units”) of a minimum amount of C$3,500,000 and a maximum of C$10,000,000 (the “Offering”). Each Unit will consist of one common share in the capital of the Company (a “Common Share”) and one Common Share purchase warrant of the Company (a “Warrant”), each Warrant entitling the holder to purchase one Common Share.

  • GlobeNewswire

    LexaGene Reports on Successful Results from Beta Testing in Human Clinical Diagnostics Laboratory

    TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today it has completed beta testing with Assurance Scientific Laboratories (ASL) in Vestavia, Alabama.  ASL is a certified reference laboratory specializing in providing clinical testing results to physicians nationwide.

  • GlobeNewswire

    LexaGene Develops Test for Deadly Mosquito-borne EEE Virus

    TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers that can rapidly detect pathogens and other molecular markers, announced today the development of a test for detection of the deadly, Eastern Equine Encephalitis (EEE) virus on its LX technology platform. EEE virus can be transmitted through the bite of an infected mosquito, and has recently caused fatal infections in Michigan, Massachusetts and Rhode Island.

  • GlobeNewswire

    LexaGene Announces its Second Hemp-Cannabis Reference Testing Laboratory as a Beta Test Site

    TSX-V: LXG) (“LexaGene”) or the (“Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today plans to place its LX Analyzer beta unit into ProVerde Laboratories, Inc. (“ProVerde”), one of the largest hemp-cannabis testing reference laboratories in Massachusetts. ProVerde Laboratories is one of three independent laboratories accredited by the state of Massachusetts to test hemp and cannabis products for contaminants such as pesticides and pathogens including bacteria, mold, or other dangerous microorganisms.

  • GlobeNewswire

    LexaGene Reports on Beta Results from Cannabis-Focused Testing Laboratory

    TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today that in August it placed a beta unit at CDX Analytics (CDX), an independent testing laboratory in Massachusetts, certified to test cannabis and hemp products for active ingredients as well as contaminants.  CDX is the first cannabis testing laboratory in Massachusetts to adopt a DNA-based microbial detection technique. The first portion of beta testing is now complete, and when the analyzer was challenged with cannabis samples containing various amounts of cannabinoids – a difficult to handle chemical compound, LexaGene’s instrument reported successful results in all runs where PCR was expected.

  • GlobeNewswire

    LexaGene to Place Beta Unit in Human Clinical Diagnostics Laboratory

    TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today it has an agreement to place a beta prototype with Assurance Scientific Laboratories (ASL) in Vestavia, Alabama in August 2019.

  • GlobeNewswire

    LexaGene Approved by CDC and FDA Antibiotic Resistance Isolate Bank to Receive Samples to Test for Superbugs

    TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced today that it has been recognized by the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) Antibiotic Resistance (AR) Isolate Bank as an institution approved to receive samples for testing antibiotic resistance.

  • GlobeNewswire

    LexaGene Files Three Additional US Patents Covering Technology

    Three US patents have been recently filed, adding to the LexaGene intellectual property portfolio. The patent applications provide continuing and additional coverage to the technology of the unique sample prep DNA extraction method, the data and image processing algorithms and the fast microfluidic PCR functions of the instrument and system. This intellectual property advancement plus existing IP are continuing to provide LexaGene with a state-of-the-art, powerful and competitive low-cost platform for genetic testing.

  • GlobeNewswire

    LexaGene’s Beta Prototype Exceeds Expectations During Testing at Massachusetts Veterinary Referral Hospital

    TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today the test results from its first beta prototype placed at the Massachusetts Veterinary Referral Hospital (Mass Vet) in Woburn, MA.  Mass Vet is one of 24 hospitals owned and operated by Ethos Veterinary Health. LexaGene’s test results were found to be 98% concordant with reference laboratory generated data.  On average, four samples were processed per day, with infections caused by E. coli, Proteus, and Staphylococcus.  During the study, the LexaGene test results correctly confirmed that 56% of the animals tested did not need antibiotics.

  • Baystreet

    Stocks in play: LexaGene Holdings Inc.

    Announced that LexaGene will host a webinar later this morning, to provide an investor focused overview ...

  • GlobeNewswire

    LexaGene Will Host a Free Webinar Providing an Overview of the Company

    TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announce that LexaGene will host a webinar today, Thursday, June 6 at 11 AM EST to provide an investor focused overview of the Company. Dr. Jack Regan, LexaGene’s Chief Executive Officer, will be leading the webinar and answering questions live. To be added to the LexaGene email distribution list, please subscribe on the Company website.

  • GlobeNewswire

    LexaGene Places its First Beta Prototype into Massachusetts Veterinary Referral Hospital

    TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today that it has placed its first beta prototype into Massachusetts Veterinary Referral Hospital (Mass Vet) in Woburn, MA.  Mass Vet is one of 24 hospitals owned and operated by Ethos Veterinary Health.

  • GlobeNewswire

    LexaGene Completes Development of Antibiotic Resistance Panel

    TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today that it has completed the development of an antibiotic resistance marker panel comprised of 12 assays targeting antibiotic resistance genes commonly found in bacterial pathogens. This further expands the Company’s capabilities in providing a complete testing solution for veterinarians to rapidly determine the cause of an infection and whether any antibiotic resistance factors are present.  This information can then be used to prescribe the most effective therapy.

  • GlobeNewswire

    LexaGene’s Technology Successfully Detects a Common Fungus That Damages Agricultural Crops

    TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced today that its LX analyzer successfully detects Botrytis cinerea, also known as Gray Mold, which is a common agricultural pathogen responsible for $10 to $100 billion in agricultural losses worldwide each year.***  This fungus infects over 200 plant species causing the most yield loss in strawberries, grapes and cannabis.

  • ACCESSWIRE

    Uptick Newswire Hosts LexaGene Holdings Inc. on The Stock Day Podcast to Discuss the Beta Launch of Their Pathogen Detection Device

    PHOENIX, AZ / ACCESSWIRE / April 24, 2019 / Uptick Newswire Stock Day Podcast welcomed LexaGene (LXXGF) (LXG.V) (''the Company''), a biotechnology company developing the very first fully automated pathogen detection platform that is open-access. President, Daryl Rebeck, joined Stock Day host Everett Jolly.

  • GlobeNewswire

    LexaGene’s Technology Identifies Genetic Mutations Directly from Cheek Swabs

    TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced today that its LX technology can successfully detect single-point gene mutations from cheek swabs.